AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$MDWD

Rubinstein Samuel purchased $7K of MDWD (indirect holdings)

Rubinstein Samuel purchased 525 indirectly-held shares of MediWound Ltd. (MDWD) at $12.62 on 2026-09-01.

Original reporting
SEC EDGAR · Rubinstein Samuel
Published Sep 2, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MDWD
Neutral
low confidence
Mentioned
$MDWD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDWDNeutralLow
01

Why it matters

The transaction is small relative to typical market volume and likely has negligible effect on MDWD's price.

02

Market read

Limited relevance; primarily of interest to investors tracking insider activity.

03

What to watch

Potential upcoming clinical data or regulatory events not disclosed.

Relevance 3/10Novelty 4/10Timing: post‑market 2026‑09‑01

Background

Form 4 filings disclose insider trades; this filing reports a director's purchase.

Company-level read

Ticker impact

$MDWDNeutralLow confidence
Context

Director Rubinstein Samuel bought 525 shares for $6,625.50 in a Form 4 filing.

Expected impact

Minimal price movement expected.

Evidence & confidence

Purchase size is modest ($6.6k) and unlikely to move the stock significantly.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider purchase could be routine compensation rather than a strong bullish signal.

Key entities

  • Company
    MediWound Ltd.

    Biotech firm listed under ticker MDWD.

  • Insider
    Rubinstein Samuel

    Director of MediWound Ltd. who made the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MDWD insider trading history →

Related articles

$MDWDMed

A sale of 1.2 million MediWound shares is expected to close around Nov. 5.

MediWound (MDWD) announced a share sale of 1.2 million ordinary shares, with H.C. Wainwright & Co. as underwriter. The deal is expected to close around Nov. 5, 2026, with gross proceeds estimated at approximately $30 million, assuming no exercise of the underwriter’s option. The company plans to use the net proceeds for working capital and general corporate purposes.

stocktitan.net
$MDWDHighAI 8/10

Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD)

MediWound (MDWD) received a $3.3M award from the U.S. Department of War to develop a room-temperature-stable version of its burn treatment gel, NexoBrid. The total program budget now stands at $21.8M. NexoBrid is FDA-approved and supported by a $197M BARDA contract with Vericel (VCEL). MediWound's market cap is approximately $170M.

investegate.co.uk
$MDWDMed

MediWound Ltd. (MDWD): Financial results for Q2 2026

MediWound Ltd. (MDWD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under it

SEC EDGAR 6-K